How Much Weight Do Patients Lose on Wegovy?
Clinical trials show Wegovy (semaglutide 2.4 mg weekly) leads to substantial weight loss in adults with obesity or overweight with comorbidities. In the STEP 1 trial, participants lost an average of 15% of body weight (about 35 pounds for a 230-pound person) after 68 weeks, compared to 2.4% on placebo. STEP 2, focused on type 2 diabetes patients, showed 9.6% average loss versus 3.4% on placebo. Real-world data aligns, with users reporting 10-20% loss over a year when combined with diet and exercise.[1][2]
Who Responds Best and What Affects Results?
Effectiveness varies by adherence, starting weight, and lifestyle. Over 80% of STEP trial participants lost at least 5% body weight, with 50%+ achieving 10-15% loss at full dose. Women and those without diabetes often see higher losses (up to 17%). Poor responders (under 5% loss) may have insulin resistance or low adherence. Diet (500-calorie deficit) and 150+ minutes weekly exercise boost outcomes by 20-30%.[1][3]
How Long Until You See Results and What Happens After Stopping?
Weight loss starts within 4 weeks (2-4% initial drop), peaks around 60-68 weeks, then plateaus. Maintenance requires ongoing use; stopping leads to 2/3 of lost weight regained within a year, per STEP 8 extension data. Long-term trials (up to 2 years) confirm sustained 10-15% loss with continued dosing.[1][4]
Wegovy vs. Other Weight Loss Drugs
Wegovy outperforms older options: liraglutide (Saxenda) averages 8% loss; phentermine-topiramate (Qsymia) 9-10%; older drugs like orlistat 5%. Compared to tirzepatide (Zepbound/Mounjaro), which averages 15-21% loss in trials, Wegovy is slightly less potent but has longer safety data. No head-to-head trials exist yet.[2][5]
What Do Side Effects and Risks Mean for Long-Term Use?
GI issues (nausea 44%, diarrhea 30%) cause 7-16% dropout but fade over time. Rare risks include pancreatitis (0.2%), gallbladder issues (2-4%), and thyroid tumors in rodents (human risk unclear). FDA warns of suicidal thoughts in some. Effectiveness holds in year 2, but 20% discontinue due to side effects. Not for cosmetic use; BMI ≥30 or ≥27 with conditions required.[1][6]
Cost, Access, and Who Can't Use It?
A 28-day supply costs $1,300-$1,700 without insurance; copays drop to $0-$25 with coverage for eligible patients. Shortages persist into 2024. Contraindicated in medullary thyroid cancer history, MEN2, or pancreatitis. Pediatric approval (12+) for obesity shows 16% loss in 68 weeks.[3][7]
Sources
[1] NEJM: Semaglutide 2.4 mg for Weight Loss (STEP 1), https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2] Novo Nordisk STEP Program Overview, https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/step-clinical-trials.html
[3] FDA Wegovy Label, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[4] Lancet: Two-Year Effects of Semaglutide, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00026-5/fulltext
[5] NEJM: Tirzepatide vs. Semaglutide (SURMOUNT), https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[6] JAMA: Real-World Semaglutide Safety, https://jamanetwork.com/journals/jama/fullarticle/2807344
[7] Novo Nordisk Investor Updates (shortages/cost), https://www.novonordisk.com